Aclaris Therapeutics Announces Results From Phase 1 Multiple Ascending Dose Trial of ATI-2138, An Investigational Oral Covalent ITK/JAK3 Inhibitor
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics has announced the results from its Phase 1 Multiple Ascending Dose Trial of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor. The results of the trial are not specified in the news.

September 18, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aclaris Therapeutics has announced the results from its Phase 1 trial of ATI-2138. The details of the results are not provided.
The announcement of the results from a Phase 1 trial is a significant event for a pharmaceutical company like Aclaris Therapeutics. However, without the details of the results, it's difficult to predict the impact on the company's stock. The news could be interpreted positively, as the company is making progress in its research, or negatively, if the lack of details suggests the results were not favorable.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100